跳至主要内容
临床试验/NCT01905462
NCT01905462已完成不适用

Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix in the United Kingdom

GlaxoSmithKline1 个研究点 分布在 1 个国家目标入组 1,046 人开始时间: 2012年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,046
试验地点
1
主要终点
Occurrence of spontaneous abortion

研究概览

简要总结

This study will assess the risk of spontaneous abortion during weeks 1-23 and weeks 1-19 of gestation, respectively, and other pregnancy outcomes, in an exposed cohort, i.e. women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix, when compared to a non-exposed cohort, i.e. women with LMP between 120 days and 18 months after the last Cervarix dose. The data collected in the Clinical Practice Research Datalink General Practitioner OnLine Database (CPRD GOLD) in the UK, will be analysed in this study.

详细描述

Convenience sampling will be used in this study. It is planned to include all eligible pregnant women (included in CPRD GOLD and who fulfil to the inclusion/exclusion criteria) in each of the two cohorts.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
15 Years 至 25 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • For the exposed cohort:
  • All subjects must satisfy all of the following criteria at entry into the exposed cohort:
  • Full date of first day of LMP available in the database or calculated from Estimated date of delivery (EDD).
  • Female, aged between, and including, 15 and 25 years of age at LMP.
  • Recorded in the CPRD GOLD for at least 12 months at LMP.
  • First day of LMP available in the database or calculated from EDD between September 1st 2008 and June 30th
  • At least one dose of Cervarix received between September 1st 2008 and June 30th
  • Full date of Cervarix vaccination(s) available.
  • First day of LMP available in the database or calculated from EDD between 30 days before and 90 days after any dose of Cervarix.
  • Subject defined as acceptable in CPRD GOLD.
  • For the non-exposed cohort:
  • All subjects must satisfy all of the following criteria at entry into the non-exposed cohort:
  • Full date of first day of LMP available in the database or calculated from EDD.
  • Female, aged between, and including, 15 and 25 years of age at LMP.
  • Recorded in the CPRD GOLD since at least 12 months at LMP.
  • First day of LMP available in the database or calculated from EDD between September 1st 2008 and June 30th
  • At least one dose of Cervarix received between September 1st 2008 and June 30th
  • Full date of Cervarix vaccination(s) available.
  • First day of LMP available in the database or calculated from EDD between 120 days and 18 months after the last dose of Cervarix.
  • Subject defined as acceptable in CPRD GOLD.

排除标准

  • For the exposed cohort:
  • Female with the first day LMP between 30 days before and 90 days after at least one dose of unspecified Human Papillomavirus vaccine and/or Gardasil.
  • For the non-exposed cohort:
  • Female with the first day LMP between 30 days before and 90 days after at least one dose of unspecified Human Papillomavirus vaccine and/or Gardasil.
  • Female included for a previous pregnancy in the exposed cohort.

结局指标

主要结局

Occurrence of spontaneous abortion

时间窗: Weeks 1-23 of gestation

次要结局

  • Occurrence of spontaneous abortion(Weeks 1-19 of gestation)
  • Occurrence of other pregnancy outcomes(12 months after last menstrual period)
  • Baby's death(First 12 weeks of baby's life)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Post-marketing Safety Study to Assess the Risk of... | 临床试验